CD39, also known as ectonucleoside triphosphate diphosphohydrolase-1 (ENTPD1), is a cell surface ectonucleotidase with key roles in modulating inflammation and localized immune regulation. Researchers from the Baker Heart and Diabetes Institute and collaborators recently proposed leveraging mRNA technologies to provide sustained, localized CD39 expression without genomic integration.
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The scientific community has explored small molecules, antibodies and nanobodies to develop ligands. Skape Bio Inc. is betting on creating miniproteins, a strategy that brings precise solutions for different functions.
A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter.
Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types.
Simcere Zaiming Pharmaceutical Co. Ltd. has divulged new mitogen-activated protein kinase (MAPK) inhibitors found to be potentially useful for the treatment of cancer.
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment, neurodegeneration and neurodevelopmental disorders, among others.
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have reported molecular glue degraders acting as proto-oncogene Vav (VAV1) degradation inducers found to be potentially useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.
Artan Biotechnologies LLC has completed a $200,000 seed raise to fund preclinical advancement of the company’s proprietary engineered suppressor platform, which targets nonsense mutations.
RSS
